Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Are your everyday habits damaging your liver? It’s not just alcohol – even sugar, painkillers, and sitting too much can take ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Although ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...